ResMed stock targets 12 to 14 percent EPS growth

Published on 09/22/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed stock targets 12 to 14 percent core EPS growth for fiscal 2027, according to MarketBeat on September 21, 2026. Revenue growth is guided at 5 to 7 percent.

Schwarzweiß-Reportagefoto eines Patienten mit Atemmaske im Schlaflabor — ResMed Inc. (ISIN US7611521078): dokumentarische Schwarzweiß-Reportage zeigt einen Patienten mit Atemmaske im Schlaflabor, Illustration mit AI erstellt.

ResMed Inc. (US7611521078) closed at USD 223.61 on the New York Stock Exchange on September 21, 2026, down 0.61 percent from USD 224.99. The company is targeting 12 to 14 percent core EPS growth for fiscal 2027, giving the stock a fundamental test beyond its recent price performance.

Growth guidance sets the tone

According to MarketBeat on September 21, 2026, ResMed expects 5 to 7 percent core constant-currency revenue growth and 12 to 14 percent core EPS growth for fiscal 2027. The outlook includes an estimated USD 75 million impact from the Astral field safety notice; excluding that effect, the reported top-line range implies 6.3 to 8.3 percent growth.

The latest quarterly figures provide the operating baseline. ResMed generated USD 1.46 billion of revenue and USD 383.43 million of earnings in Q4 fiscal 2026, with a 26.20 percent profit margin, according to the company data presented on Yahoo Finance. Quarterly EPS of USD 2.95 exceeded the USD 2.89 estimate by USD 0.06, a quantified comparison that supports the earnings-growth target.

GLP-1 data adds a demand angle

ResMed's management said the company is tracking 2.5 million de-identified patients prescribed both positive airway pressure therapy and GLP-1 treatments. The GLP-1 group showed an 11-percentage-point higher therapy-start rate than the control group, while its one-year resupply rate was 300 basis points higher.

That evidence gives the guidance a specific demand driver, but the cost backdrop remains material. Management said gross margin had expanded by more than 500 basis points over three years, while freight, fuel, logistics and component costs were increasing. ResMed also expects annual gross-margin improvement of low double-digit basis points through fiscal 2030, according to MarketBeat on September 21, 2026.

Stock remains below yearly high

At USD 223.61 on September 21, 2026, ResMed stock stood USD 61.26 below its 52-week high of USD 284.87 and USD 43.34 above its 52-week low of USD 180.27. The market capitalization was USD 32.256 billion, and trading volume reached 699,060 shares on that session.

The next reporting date shown by Yahoo Finance is October 29, 2026. Until then, the key measurable comparison is between the fiscal 2027 guidance and the latest quarter: projected core EPS growth of 12 to 14 percent versus quarterly revenue of USD 1.46 billion and EPS of USD 2.95 in Q4 fiscal 2026.

ResMed stock closes at USD 223.61

ResMed stock closed at USD 223.61 on the New York Stock Exchange on September 21, 2026, down 0.61 percent from the previous close. The quoted 52-week range was USD 180.27 to USD 284.87, while market capitalization stood at USD 32.256 billion.